Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks
Vor Biopharma Inc. (VOR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:VOR) 2026-01-16